Tilray Medical Study Finds Oral THC:CBD Extract Offers Faster, Higher Bioavailability

Tilray Brands Inc. (NASDAQ:TLRY) is one of the best penny stocks under $1 to buy now. On June 26, Tilray Brands, through its medical division, Tilray Medical, published a new scientific study on the bioavailability of different cannabinoid formulations.

This research, conducted on healthy volunteers, compared Tilray’s oral THC:CBD extract with oromucosally administered nabiximols.

Tilray Medical Study Finds Oral THC:CBD Extract Offers Faster, Higher Bioavailability

A busy pharmaceutical lab with technicians developing hemp-derived CBD products.

The findings show that Tilray’s oral extract resulted in higher and faster concentrations of THC and CBD in the bloodstream.

Tilray Brands Inc. (NASDAQ:TLRY) is a lifestyle consumer products company that researches, cultivates, processes, and distributes medical cannabis products in Canada, the US, Europe, Australia, New Zealand, Latin America, and internationally.

While we acknowledge the potential of TLRY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TLRY and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.